What is the most recent earnings date for ARWR stock?
ARROWHEAD PHARMACEUTICALS IN (ARWR) last reported earnings on 2/5/2026.
ARROWHEAD PHARMACEUTICALS IN (ARWR) Earnings History & Surprises
NASDAQ:ARWR • US04280A1007
Current stock price
57.78 USD
-2.99 (-4.92%)
At close:
57.78 USD
0 (0%)
After Hours:
ARWR Earnings overview
Past quarterly earnings results for ARROWHEAD PHARMACEUTICALS IN (ARWR), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 11, 2026
- Period
- Q2 / 2026
- EPS Estimate
- -$1.21
- Revenue Estimate
- 77.204M
Last Reported
Most Recent- Release Date
- Feb 5, 2026
- Period
- Q1 / 2026
- EPS Reported
- $0.22
- EPS Surprise
- -14.75%
- Revenue Surprise
- -4.15%
Beat Rate
Last 8 Quarters 31%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q1 2026 | 0.22 | 0.26 | -14.75% | 115.83% | 264.033M | 275.47M | -4.15% | 10,461.32% |
| Q4 2025 | -0.18 | -0.25 | 26.70% | 86.86% | 256.472M | 179.38M | 42.98% | - |
| Q3 2025 | -1.26 | -1.05 | -20.51% | 8.70% | 27.767M | 24.185M | 14.81% | - |
| Q2 2025 | 2.75 | -0.20 | 1,461.66% | 369.61% | 543M | 30.504M | 1,680.09% | - |
| Q1 2025 | -1.39 | -0.45 | -211.36% | -12.10% | 2.5M | 74.205M | -96.63% | -29.60% |
| Q4 2024 | -1.37 | -1.07 | -28.19% | -34.31% | 65.099M | -100.00% | -100.00% | |
| Q3 2024 | -1.38 | -0.56 | -145.24% | -43.75% | 53.688M | -100.00% | -100.00% | |
| Q2 2024 | -1.02 | -0.17 | -515.69% | -326.67% | 65.147M | -100.00% | -100.00% | |
| Q1 2024 | -1.24 | -0.84 | -48.25% | -217.95% | 3.551M | 30.101M | -88.20% | -94.32% |
| Q4 2023 | -1.02 | -0.62 | -65.77% | -25.93% | 16.097M | 51.743M | -68.89% | -49.06% |
| Q3 2023 | -0.96 | -0.67 | -44.13% | -41.18% | 15.825M | 50.169M | -68.46% | -51.16% |
| Q2 2023 | 0.45 | -0.65 | 168.84% | 9.76% | 146.267M | 46.389M | 215.31% | -3.64% |
| Q1 2023 | -0.39 | 0.45 | -187.62% | 35.00% | 62.5M | 165.77M | -62.30% | 128.10% |
| Q4 2022 | -0.81 | -0.17 | -379.95% | -32.79% | 31.6M | 51.453M | -38.58% | -17.49% |
| Q3 2022 | -0.68 | -0.52 | -31.80% | -134.48% | 32.4M | 56.332M | -42.48% | -29.41% |
| Q2 2022 | 0.41 | -0.08 | 596.25% | 257.69% | 151.8M | 111.09M | 36.65% | 362.80% |
| Q1 2022 | -0.60 | -0.46 | -31.60% | -200.00% | 27.4M | 52.065M | -47.37% | 28.64% |
| Q4 2021 | -0.61 | -0.11 | -467.08% | -27.08% | 38.3M | 57.91M | -33.86% | 403.95% |
| Q3 2021 | -0.29 | -0.20 | -44.10% | -123.08% | 45.9M | 38.267M | 19.95% | 67.52% |
| Q2 2021 | -0.26 | -0.13 | -94.14% | -30.00% | 32.8M | 38.451M | -14.70% | 39.57% |
| Q1 2021 | -0.20 | 0.12 | -266.32% | -566.67% | 21.3M | 77.076M | -72.36% | -27.80% |
| Q4 2020 | -0.48 | 0.12 | -504.42% | - | 7.6M | 50.227M | -84.87% | - |
| Q3 2020 | -0.13 | -0.12 | -9.87% | - | 27.4M | 29.49M | -7.09% | - |
| Q2 2020 | -0.20 | -0.11 | -80.07% | - | 23.5M | 22.175M | 5.98% | - |
| Q1 2020 | -0.03 | -0.01 | -311.93% | - | 29.5M | 30.09M | -1.96% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
363.28%
Max EPS beat (4)
1,461.66%
Min EPS beat (4)
-20.51%
Revenue beat statistics
Revenue beat (4)
3
Average Revenue beat (4)
433.43%
Max Revenue beat (4)
1,680.09%
Min Revenue beat (4)
-4.15%
Analysis
In the last 4 quarters, ARWR has beaten EPS estimates in 2 out of 4 releases
ARWR has beaten revenue estimates in 3 out of the last 4 releases
In the last 4 quarters, ARWR has beaten the EPS estimates by 363.3% on average.
In the last 4 quarters, ARWR has beaten the revenue estimates by 433.4% on average.
Related analysis
ARROWHEAD PHARMACEUTICALS IN / ARWR Earnings FAQ
Did ARROWHEAD PHARMACEUTICALS IN (ARWR) beat earnings estimates last quarter?
ARROWHEAD PHARMACEUTICALS IN (ARWR) missed EPS estimates and missed revenue estimates in the most recent quarter.
What percentage of the time does ARWR stock beat earnings estimates?
In the last 4 quarters, ARROWHEAD PHARMACEUTICALS IN (ARWR) has beaten EPS estimates in 2 out of 4 releases.